Verition Fund Management LLC lowered its holdings in GH Research PLC (NASDAQ:GHRS - Free Report) by 7.3% in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 1,057,782 shares of the company's stock after selling 82,850 shares during the quarter. Verition Fund Management LLC owned approximately 2.03% of GH Research worth $7,077,000 at the end of the most recent reporting period.
Separately, Lynx1 Capital Management LP raised its stake in GH Research by 19.8% in the second quarter. Lynx1 Capital Management LP now owns 3,966,726 shares of the company's stock worth $46,252,000 after buying an additional 656,163 shares in the last quarter. Hedge funds and other institutional investors own 56.90% of the company's stock.
GH Research Price Performance
NASDAQ GHRS traded down $0.25 on Monday, hitting $8.68. The stock had a trading volume of 73,156 shares, compared to its average volume of 79,043. The business's fifty day moving average price is $8.04 and its 200 day moving average price is $10.16. The stock has a market cap of $451.60 million, a price-to-earnings ratio of -11.52 and a beta of 0.74. GH Research PLC has a 52-week low of $5.05 and a 52-week high of $14.99.
GH Research (NASDAQ:GHRS - Get Free Report) last announced its earnings results on Tuesday, September 3rd. The company reported ($0.20) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.23) by $0.03. As a group, sell-side analysts anticipate that GH Research PLC will post -0.79 EPS for the current year.
Analyst Ratings Changes
Several brokerages have issued reports on GHRS. Canaccord Genuity Group dropped their target price on GH Research from $31.00 to $28.00 and set a "buy" rating on the stock in a research report on Monday, November 18th. HC Wainwright reaffirmed a "buy" rating and set a $40.00 price objective on shares of GH Research in a research report on Wednesday, November 20th. Finally, JMP Securities reiterated a "market outperform" rating and issued a $39.00 target price on shares of GH Research in a research note on Wednesday, September 4th.
Check Out Our Latest Report on GH Research
About GH Research
(
Free Report)
GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD).
Read More
Before you consider GH Research, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and GH Research wasn't on the list.
While GH Research currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
